- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04406207
Endogenous Retroviruses in Acute Myeloid Leukemia (ERVAL)
Human Endogenous Retroviruses in Acute Myeloid Leukemia: Expression and Immune Impact
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for numerous malignant hematologic diseases. Despite recent advances in the field, relapse rates are still high and the first cause of death. The identification of new relevant therapeutic targets is therefore urgently needed.
Human endogenous retroviruses (HERVs) are accounting for 8% of the human genome. While silenced at the steady state (mainly by methylation mechanisms), HERVs reactivations have been described in different conditions such as auto-immune diseases or cancer, leading to an innate and adaptive immune response. Several questions are raised in the field of hematology where few data are available, and the exact role of HERVs in these diseases is still to define.
Our team is currently working on the role of HERVs in different types of cancer. We developed a bioinformatics approach to identify overexpressed HERVs from RNAseq data. We also developed in vitro assays to assess the immunogenicity of different peptides from HERVs open reading frames and showed that several epitopes shared among different HERVs can induce a specific CD8+ T cell response. More recently, we have analyzed 151 acute myeloid leukemia (AML) RNAseq data from TCGA and identified multiple overexpressed HERVs in this disease. Immunogenicity test are currently ongoing with patient's blood at diagnosis.
The main objective of this part of our project is to analyze the establishment of a HERVs-specific CD8+ T cell response participating in graft-versus-leukemia effect after HSCT for AML patients. Secondary objectives are to analyze relations between this response and different clinical factors such as the onset of GVHD or relapse.
Peripheral blood mononuclear cells (PBMCs) from AML patients will be extracted and frozen at different time point: diagnosis, complete remission (pre-HSCT) and after HSCT (M3, M6 and M12). This prospective protocol is currently ongoing at the Centre Hospitalier Lyon Sud, with around 30 samples already available.
After having selected relevant HERVs, specific dextramers identified by DNA barcode will be synthesized. These dextramers allowing the identification of specific T cell responses directed against up to 1000 epitopes, we will be able to screen specific T cells directed against HERVs overexpressed in AML for most common HLA. Dextramer staining will be performed on PBMCs after thawing. Positive cells will be sorted by flow cytometry and DNA will be expanded by PCR before performing sequencing, allowing the identification of specific sequences by its unique DNA barcode.
The analyze of HERVs-specific CD8+ T cell responses after HSCT will allow us to better define HERVs role in the onset of graft-versus-leukemia effect. A specific T cell response without GvHD will define the relevance of such peptides as tumor specific antigens.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Acute myeloid leukemia (all subtypes)
- Stem cell transplantation indication
- Non opposition to the study
Exclusion Criteria:
- Intensive care unit at diagnosis
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients
Patients relapsing or not after hematopoietic stem cell transplantation.
|
Evaluation of HERVs-specific CD8+ T cells before and after hematopoietic stem cell transplantation. Comparison will be made in patients relapsing vs non relapsing patients. The measurement of these responses will be done by dextramer, allowing precise and specific measurement of the lymphocytes directed against the HERVs of interest. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HERVs-specific CD8+ T cells responses
Time Frame: Day 0
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
Day 0
|
HERVs-specific CD8+ T cells responses
Time Frame: At remission <- Day 0 + 1 month
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
At remission <- Day 0 + 1 month
|
HERVs-specific CD8+ T cells responses
Time Frame: Before transplant <- Day 0 + 3 month
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
Before transplant <- Day 0 + 3 month
|
HERVs-specific CD8+ T cells responses
Time Frame: 1 month
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
1 month
|
HERVs-specific CD8+ T cells responses
Time Frame: 3 months
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
3 months
|
HERVs-specific CD8+ T cells responses
Time Frame: 6 months
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
6 months
|
HERVs-specific CD8+ T cells responses
Time Frame: 12 months
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
12 months
|
HERVs-specific CD8+ T cells responses
Time Frame: At relapse: up to 6 month after day 0
|
HERVs-specific CD8+ T cells responses will be monitored using DNA-barcode dextramers.
|
At relapse: up to 6 month after day 0
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vincent ALCAZER, MD, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL19_0851
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Yale UniversityPfizerTerminatedACUTE MYELOID LEUKEMIAUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
Clinical Trials on Demonstration of T cell responses
-
St. Jude Children's Research HospitalActive, not recruiting
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Combined Military Hospital, PakistanCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedPhysical ActivityGermany
-
Beijing GoBroad HospitalRecruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic LeukemiaChina
-
Hadassah Medical OrganizationCompleted